Display options
Cite
Guarnieri M, Brayton C, Sarabia-Estrada R, et al. Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats. J Vet Med. 2017;2017:3102567doi: 10.1155/2017/3102567.
Guarnieri, M., Brayton, C., Sarabia-Estrada, R., Tyler, B., McKnight, P., & DeTolla, L. (2017). Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats. Journal of veterinary medicine, 20173102567. https://doi.org/10.1155/2017/3102567
Guarnieri, M, et al. "Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats." Journal of veterinary medicine vol. 2017 (2017): 3102567. doi: https://doi.org/10.1155/2017/3102567
Guarnieri M, Brayton C, Sarabia-Estrada R, Tyler B, McKnight P, DeTolla L. Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats. J Vet Med. 2017;2017:3102567. doi: 10.1155/2017/3102567. Epub 2017 Apr 09. PMID: 28492060; PMCID: PMC5401735.
Copy Download .nbib Format: NLM
Share it on

J Vet Med. 2017;2017:3102567. doi: 10.1155/2017/3102567. Epub 2017 Apr 09.

Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats.

Journal of veterinary medicine

M Guarnieri, C Brayton, R Sarabia-Estrada, B Tyler, P McKnight, L DeTolla

Affiliations

  1. Johns Hopkins School of Medicine, Department of Neurological Surgery, Baltimore, MD, USA.
  2. Johns Hopkins School of Medicine, Department of Molecular and Comparative Pathobiology, Baltimore, MD, USA.
  3. George Mason University, Fairfax, VA, USA.
  4. University of Maryland School of Medicine, Departments of Pathology, Medicine, Epidemiology and Public Health and the Program of Comparative Medicine, Baltimore, MD, USA.

PMID: 28492060 PMCID: PMC5401735 DOI: 10.1155/2017/3102567

Abstract

A Target Animal Safety protocol was used to examine adverse events in male and female Fischer F344/NTac rats treated with increasing doses of a subcutaneous implant of a lipid suspension of buprenorphine. A single injection of 0.65 mg/kg afforded clinically significant blood levels of drug for 3 days. Chemistry, hematology, coagulation, and urinalysis values with 2- to 10-fold excess doses of the drug-lipid suspension were within normal limits. Histopathology findings were unremarkable. The skin and underlying tissue surrounding the drug injection were unremarkable. Approximately 25% of a cohort of rats given the excess doses of 1.3, 3.9, and 6.5 mg/kg displayed nausea-related behavior consisting of intermittent and limited excess grooming and self-gnawing. These results confirm the safety of cholesterol-triglyceride carrier systems for subcutaneous drug delivery of buprenorphine in laboratory animals and further demonstrate the utility of lipid-based carriers as scaffolds for subcutaneous, long-acting drug therapy.

References

  1. Psychopharmacology (Berl). 2001 Nov;158(2):154-64 - PubMed
  2. MMW Fortschr Med. 2011 Jan 13;152 Suppl 4:125-32 - PubMed
  3. Xenobiotica. 1985 Apr;15(4):287-97 - PubMed
  4. Lab Anim (NY). 2012 Nov;41(11):337-43 - PubMed
  5. Lab Anim (NY). 2010 Aug;39(8):236-40 - PubMed
  6. Lab Anim. 2014 Apr 23;48(3):216-224 - PubMed
  7. Pharmacol Biochem Behav. 1983 Mar;18(3):471-4 - PubMed
  8. Drug Deliv Transl Res. 2012 Aug;2(4):238-53 - PubMed
  9. Anesthesiology. 2011 Dec;115(6):1251-60 - PubMed
  10. Lab Anim Sci. 1998 Feb;48(1):5 - PubMed
  11. Lab Anim. 2002 Jul;36(3):322-43 - PubMed
  12. Lab Anim (NY). 2014 Oct;43(10):364-71 - PubMed
  13. Lab Anim (NY). 2009 Mar;38(3):87-93 - PubMed
  14. Pharm Res. 2008 May;25(5):1052-62 - PubMed
  15. Br J Anaesth. 2005 Jun;94(6):825-34 - PubMed
  16. Comp Med. 2009 Feb;59(1):60-71 - PubMed
  17. J Am Assoc Lab Anim Sci. 2011 Mar;50(2):198-204 - PubMed
  18. J Pain Symptom Manage. 1999 Oct;18(4):280-8 - PubMed
  19. Eur J Pharmacol. 2011 Jan 25;651(1-3):89-95 - PubMed
  20. Lab Anim. 2015 Apr;49(2):100-10 - PubMed
  21. J Med Chem. 2016 Sep 22;59(18):8621-33 - PubMed
  22. Addiction. 2006 Mar;101(3):420-32 - PubMed
  23. Lab Anim (NY). 2016 Jan;45(1):28-34 - PubMed
  24. Pain Pract. 2008 Jul-Aug;8(4):287-313 - PubMed
  25. Eur J Pharmacol. 2004 May 10;492(1):27-34 - PubMed
  26. Anesth Analg. 1994 Oct;79(4):706-9 - PubMed
  27. Am J Clin Nutr. 1977 Feb;30(2):147-50 - PubMed
  28. J Pharmacol Exp Ther. 1988 Aug;246(2):449-53 - PubMed
  29. J Am Assoc Lab Anim Sci. 2014 Sep;53(5):494-501 - PubMed
  30. J Am Assoc Lab Anim Sci. 2013 Jan;52(1):48-56 - PubMed
  31. Lab Anim. 2012 Oct;46(4):349-51 - PubMed
  32. Physiol Behav. 2009 Apr 20;97(1):87-90 - PubMed
  33. Curr Med Res Opin. 2005 Aug;21(8):1147-56 - PubMed
  34. Life Sci. 2004 Apr 16;74(22):2685-91 - PubMed
  35. Neuro Oncol. 2011 Jul;13(7):700-9 - PubMed
  36. Pharmacol Biochem Behav. 1988 Feb;29(2):393-6 - PubMed
  37. J Pharm Bioallied Sci. 2014 Jan;6(1):43-7 - PubMed
  38. Vet J. 2011 Mar;187(3):335-41 - PubMed
  39. Comp Med. 2004 Jun;54(3):293-300 - PubMed
  40. J Pharmacol Exp Ther. 1997 Aug;282(2):769-78 - PubMed
  41. Lab Anim. 2001 Jul;35(3):213-22 - PubMed
  42. Toxicol Lett. 2009 Dec 15;191(2-3):327-40 - PubMed
  43. Br J Pharmacol. 1977 Aug;60(4):547-54 - PubMed
  44. Pharmacol Biochem Behav. 1993 Aug;45(4):817-21 - PubMed
  45. J Radiat Res. 2002 Jun;43(2):135-41 - PubMed
  46. Vet Anaesth Analg. 2013 Sep;40(5):537-45 - PubMed
  47. J Am Assoc Lab Anim Sci. 2012 Nov;51(6):815-9 - PubMed
  48. J Am Assoc Lab Anim Sci. 2014 Jul;53(4):387-91 - PubMed
  49. Contemp Top Lab Anim Sci. 2000 Mar;39(2):8-13 - PubMed
  50. Lab Anim. 2000 Apr;34(2):202-6 - PubMed
  51. J Am Vet Med Assoc. 2016 Apr 1;248(7):795-801 - PubMed
  52. J Biomed Mater Res. 1989 Feb;23(2):253-66 - PubMed

Publication Types